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Abstract
The common fruit fly Drosophila melanogaster (Dm) is a simple animal species that contrib-
uted significantly to the development of neurobiology whose leucine-rich repeat kinase 2
mutants (LRRK2) loss-of-function in the WD40 domain represent a very interesting tool to
look into physiopathology of Parkinson’s disease (PD). Accordingly, LRRK2 Dm have also
the potential to contribute to reveal innovative therapeutic approaches to its treatment.With-
ania somnifera Dunal, a plant that grows spontaneously also in Mediterranean regions, is
known in folk medicine for its anti-inflammatory and protective properties against neurode-
generation. The aim of this study was to evaluate the neuroprotective effects of its standard-
ized root methanolic extract (Wse) on the LRRK2 loss-of-function Dmmodel of PD. To this
end mutant and wild type (WT) flies were administeredWse, through diet, at different con-
centrations as larvae and adults (L+/A+) or as adults (L-/A+) only. LRRK2 mutants have a
significantly reduced lifespan and compromised motor function and mitochondrial morphol-
ogy compared to WT flies 1%Wse-enriched diet, administered to Dm LRRK2 as L-/A+and
improved a) locomotor activity b) muscle electrophysiological response to stimuli and also
c) protected against mitochondria degeneration. In contrast, the administration ofWse to
Dm LRRK2 as L+/A+, no matter at which concentration, worsened lifespan and determined
the appearance of increased endosomal activity in the thoracic ganglia. These results,
while confirming that the LRRK2 loss-of-function in the WD40 domain represents a valid
model of PD, reveal that under appropriate concentrationsWse can be usefully employed to
counteract some deficits associated with the disease. However, a careful assessment of
the risks, likely related to the impaired endosomal activity, is required.
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Introduction
Parkinson’s disease (PD) is the second most common neurodegenerative disorder[1] affecting
2% of the population over 60 years with an increasing incidence over age 85 [2]. The progres-
sive loss of dopaminergic neurons in the substantia nigra of the midbrain leads to a deficiency
of dopamine causing the typical motor symptoms such as tremor, bradykinesia and rigidity [3]
[4]. Although the etiopathogenesis is not fully understood and most cases seem sporadic,
genetic variables play a key role in the predisposition to PD onset with at least 5 to 10% of PD
patients clearly associated with genetic factors[5]. Indeed, since the seminal paper of Polymero-
poulos et al. [6], which identified the first mutation related to PD in the alpha-synuclein gene,
other genes involved in the etiology of familial forms of parkinsonism have been discovered[7–
15]. Among them, the identification of several leucine-rich repeat kinase 2 (LRRK2) gene
mutations has opened a novel scenario in Parkinson’s disease genetics[16]. In fact, the G2019S
LRRK2 mutation is the most common in Caucasian patients occurring in 1–2% of sporadic
cases of PD [17][18], while other mutations, such as the G2385R variants contribute to the sus-
ceptibility to develop PD especially in Chinese patients[19]. LRRK2 encodes for a protein with
a number of independent domains that is expressed, although at a low level, in all tissues. In
the brain it is found in the cortex, striatum, hippocampus, cerebellum, and at the level of the
dopaminergic neurons in the substantia nigra [20–23]. Most mutations of this gene are associ-
ated with a late onset Parkinsonism [15]. Mutations of the gene LRRK2 that elicit the disease
occur at the level of the functional domain Roc (R1441C and G), at the level of the COR
(Y1699C and R1628P) and of MAPKKK domains (G2019S and I2020T) and in only one of the
WD40 domains (G2385R)[11][15][24]. This latter is known to be crucial in several basic cell
functions such as vesicle sorting during endocytosis and exocytosis of synaptic vesicles as well
as vesicle-mediated transport and cytoskeleton assembly [25][26]. The role of the WD40
domain is suggested to be crucial in controlling the LRRK2-regulated kinase activity having a
critical role in the self-interaction and autophosphorylation-mediated mechanisms of neuronal
toxicity [27]. Accordingly, deletion of this domain has been shown in-vitro to cause the reduc-
tion of the kinase activity that is restored over-expressing the gain of function mutation of the
gene[28].
Translational animal models are particularly useful in studying neuronal dysfunction and
investigating the etiology and molecular aspects of neurodegenerative diseases. Among the ani-
mal species that significantly contributed to the development of these studies, the Drosophila
melanogaster (Dm) represents a simple, yet experimentally and translationally powerful, organ-
ism that contributed significantly not only to the development of neurobiology but also to the
progress of knowledge on neurodegenerative diseases. Notably, most of the genes implicated in
familial forms of PD have a counterpart in this insect [29], and Dmmutants of PD have been
genetically engineered to model key features of the human condition and have been success-
fully used in studying PD pathogenesis and in exploring new strategies of disease treatment
[30–33]. Previous studies on LRRK2 PD form using Dmmutants (dLRRK2) did not clarify the
role of LRRK2 in Drosophila, both in mutants gain-of-function for the kinase domain[15][34]
and loss-of-function (LRRKex1 mutant) [35–37].
Fully effective medications to treat neurodegenerative diseases are currently lacking and the
discovery of novel drug targets for long-sought therapeutics is a great challenge for researchers
and clinicians. The use of plant extracts is largely employed worldwide in traditional medicine,
constituting the basis of health care in many societies, to treat disparate pathologies [38]. The
well-known therapeutic properties of the medicinal plants have been investigated in various
animal models and the observations of such investigations have served in many instances as
the basis of new drugs development [39][40][33]. A common plant of the Indian flora, also
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found in Southern Europe, including Sardinia (Italy), isWithania somnifera (Ws) Dunal. Its
roots, used in Ayurvedic medicine for many central nervous system disorders [41][42], are a
valuable herbal medication and the recognized pharmacological effects ofWs, such as anti-oxi-
dant, neuroprotection and functional recovery made it of prime interest also in the treatment
of PD [43][44].
The aim of this paper was twofold: on one hand to confirm the validity of the LRRKex1mu-
tant [35][37], from now on named LRRK2 WD40 loss-of-function (LRRK2WD40), as animal
model of parkinsonism in Dm; on the other hand, to investigate the antiparkinsonian potential
of the standardized methanolic extract ofWse roots on this mutant, as compared to Dm wild
type (WT, Canton-S). To this end we tested lifespan, climbing activity, electrophysiological
muscle parameters and subcellular ultrastructure (mitochondria and lysosomes) of the neurons
involved in the motor circuitry, as those present in the Dm thoracic ganglia.
Materials and Methods
For these experiments we used adult wild type (WT; Canton -S) and LRRK2WD40mutant
(LRRKex1, #34750, from Bloomington Stock Center) Drosophila melanogaster (Dm) males.
After emergence from pupae, WT and LRRK2 mutant males were separated. WT and mutant
flies were reared on a standard cornmeal-yeast-agar medium in controlled environmental con-
ditions (24–25°C; 60% relative humidity; light/dark = 12/12 hours). In addition, groups of
mutant andWT flies were reared on a standard medium supplemented with the standardized
methanolic extract ofWithania somnifera root (Wse) (gift of Natural Remedies Ltd, Bangalore,
India) at three different concentrations (0.1, 1 and 10% w/w) whereas other independent
groups of WT and mutant flies were reared with 0.01% (0.5 mM) L-3,4-dihydroxyphenylala-
nine (L-Dopa).Wse and L-Dopa were added once the mixture was stirred for 10 min and had
cooled down sufficiently[45].All treatments were performed in two combinations concerning
their life cycle: as adults (L-/A+) or from larvae and adults (L+/A+). Standard genetic procedures
were used during the study.
Survival curves
With the aim of selecting the optimalWse’s concentration to perform the whole study, Dm
were grown on standard diet supplemented with different concentrations ofWse at 25°C.
Cohorts of 60 flies (6 flies/tube) from each experimental group (i.e.Wse-untreated andWse-
treated WT,Wse-untreated andWse-treated LRRK2WD40) were monitored every 2 days for
their survival. Mortality was analyzed using Kaplan-Meier survival curves and the statistical
comparisons were made with a Gehan-Breslow-Wilcoxon test. All experiments were done in
triplicate.
Climbing assay
The climbing assay (negative geotaxis assay) was used to assess locomotor ability [46]. Climb-
ing data were obtained from different age groups (I: 3–6; II: 10–15; III: 20–25 days old) of
untreated-WT,Wse-untreated andWse-treated LRRK2WD40 mutants. Cohorts of 30 flies from
each experimental group were subjected to the assay. Flies were placed individually in a verti-
cally-positioned plastic tube (length 10 cm; diameter 1.5 cm) and tapped to the bottom. Climb-
ing time (s) was recorded upon crossing a line drawn at 6 cm from the bottom. The number of
flies that could climb unto, or above, this line within 10 seconds was recorded and expressed as
percentage of total flies. Data were expressed as average ± standard error of the mean (SEM)
from three experiment replications. Statistically significant differences (p<0.05) among WT,
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Wse-untreated andWse-treated LRRK2WD40 were indicated. The statistical evaluation was
made with a one-way analysis of variance (ANOVA) followed by LSD post-hoc test.
Electrophysiological recordings
At the time of the experiments, flies from group II were anesthetized by using CO2 and care-
fully anchored to a wax support ventral side down, as previously reported [47][48]and placed
underneath a stereomicroscope. In details, two tungsten stimulating electrodes, connected to a
stimulator (Master 8, A.M.P.I, Jerusalem, IL) and a stimulus isolation unit (DS2A, Digitimer
Ltd., Hertfordshire, UK) were placed into both eyes of the fly in order to activate the Giant
Fiber System (GFS). Stimulus intensity and duration were adjusted in every single experiment
until the muscle response was detected; maximal stimulation intensity was not greater than 10
V, and stimulus duration was not greater than 0.5 ms. A ground tungsten wire was placed into
the fly abdomen. A borosilicate recording electrode, shaped by a puller (P97, Sutter Instru-
ments, Novato, CA) with a resistance of 40-50MO when filled with 3M KCl, was placed into
the right or left backside of the fly in order to record Post Synaptic Potentials (PSPs) from the
Dorsal Longitudinal Muscle fibers (DLMs). PSPs were recorded with an Axopatch 2-B ampli-
fier (Axon Instruments, Foster City, CA), filtered at 0.5 kHz and digitized at 1 kHz. PSPs were
recorded in bridge mode, measured using peak and event detection software pCLAMP 8.2
(Axon Instruments, Foster City, CA) and analyzed off-line by pCLAMP fit software (Axon
Instruments, Foster City, CA). All recordings were obtained from at least 10 different flies
belonging to each experimental group (i.e. WT,Wse-untreated andWse-treated LRRK2WD40).
Experimenters were blind to the treatment.
Additional electrophysiological experiments were performed by applying a protocol consist-
ing in a single GFS stimulation, delivered every 20 s, followed by PSPs recording. In this differ-
ent set of experiments, the “frequency of following” was determined by delivering trains of 10
stimuli at frequencies of 100 Hz (with 10 ms between stimuli) or 200 Hz (with 5 ms between
stimuli). Data are expressed as mean + SEM and one or two-way ANOVA followed by Tukey’s
or Bonferroni’s post-hoc test (p<0.05), were used in order to determine significant differences
between groups.
Electron microscopy analysis
DrosophilaeWT,Wse-untreated andWse-treated at 1% (L-/A+) and 10% (L+/A+) LRRK2WD40
from group II were anesthetized with CO2 before brains and thoracic ganglia being rapidly dis-
sected out and fixed in a mixture of 2% glutaraldehyde and 2% paraformaldehyde in 0.1 M
cacodylate buffer. After several rinsing in the same buffer, the samples were post-fixed in 1%
osmium tetroxide in 0.1 M cacodylate buffer for 2 h and stained overnight at 4°C in aqueous
0.5% uranyl acetate solution. Then the samples were washed several times in distilled water,
dehydrated in a graded ethanol series and then embedded in SPURR resin. Roughly 70 nm
thick sections, corresponding to portions of the thoracic ganglia and antennal lobes (ALs;
homologous to olfactory bulbs in vertebrates), were cut with a Diatomediamond knife on a
Leica EM UC6 ultramicrotome. (Leica Microsystems, Germany). Images were obtained with a
FEI Tecnai G2 F20 (FEI Company, The Netherlands) transmission electron microscope
equipped with a Shotky field emission gun operating at an acceleration voltage of 80 kV and
recorded with a 2k x 2k Ultrascan Gatan CCD camera (Gatan, USA).
Drug Effects ofWithania somnifera in a LRRK2 Drosophila Model
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Results
Effects ofWse on the lifespan of LRRK2WD40
Fig 1A shows that LRRK2WD40 mutants exhibit a significantly shorter life span than WT con-
trols. To evaluate a possible toxic effect,Wse was tested at different concentrations (0.1, 1 and
10% w/w in their standard diet) as L-/A+ onto WT insects. In this respect, no significant effects
were detected at anyWse concentration but 10% which significantly reduces the duration of
life (Fig 1B) as compared to untreated WT controls. To evaluate the influence of the extract of
Wse on the duration of life of the LRRK2WD40 mutants that, as reported above, demonstrated a
reduced life span in respect to untreated- WT, they were treated withWse at the same concen-
trations as L-/A+ (Fig 1C) or as L+/A+ (Fig 1D). As shown by the Kaplan-Meier survival curves,
administration ofWse induces a statistically significant increase, even if by a different extent,
in the lifespan of mutants LRRK2WD40, when the insects were fed in the adult stage only at
0.1% and especially 1% concentrations (p<0.05 Breslow-Gehan-Wilcoxon test). This restoring
effect was lost when insects were treated at10%Wse L-/A+ (Fig 1C), and at any concentration
when administrated to larvae and adults (L+/A+) LRRK2WD40(Fig 1D).The overall results are
in accordance with the hypothesis thatWse accumulation, due to high concentration and/or
long period administration, can induce a possible toxic effect.
Fig 1. Effects ofWse on lifespan. (A) Lifespan, expressed as % survival rates, of wild type (WT) and LRRK2 flies. (B) Lifespan of untreatedWT compared
to treatedWT, only when adults (L-/A+), withWse, 0.1%, 1% and 10%. (C)Lifespan of untreated LRRK2 mutants compared to treated LRRK2mutants, only
when adults (L-/A+), withWithania somnifera extract (Wse), 0.1%, 1% and 10%. (D) Lifespan of untreated LRRK2mutants compared to treated LRRK2
mutants, from their larval stage to the end of their life-cycle (L+/A+), withWse, 0.1%, 1% and 10%. *indicates p<0.05 at Kaplan-Meier survival curves (Gehan-
Breslow–Wilcoxon—Graph Pad Prism 5.01), (A) untreated LRRK2 compared to untreatedWT, (B) untreatedWT compared to treatedWT and (C-D)
untreated LRRK2 compared to treated LRRK2.
doi:10.1371/journal.pone.0146140.g001
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Effect ofWse on the locomotor ability of LRRK2WD40
According to results obtained followingWse administration paralleled with life span we
decided to testWse at 1% w/w effects on the climbing activity (negative geotaxis) of mutants.
Fig 2A shows a significant increase in the climbing time in the threeage groups tested (I: 3–6;
II: 10–15; III: 20–25 days old) of LRRK2WD40 as compared to subjects of the WT group
(p<0.001) with a tendency to deterioration of the motor performance with aging. The exposure
of LRRK2WD40 to 1% w/wWse as L-/A+, induces, in groups I and II, the recovery of motor dis-
ability showing a significant decrease of time to climb compared to untreated mutants; a simi-
lar result was also found in insects of groups I-II that were fed 1%Wse from larvae and adults
(L+/A+). On the other hand,Wse administration both to L-/A+ and L+/A+ failed to significantly
ameliorate motor behavior in group III aged flies with respect to untreated mutants. L-/A+ flies
treated withWse showed a clear tendency toward rescue.
Moreover, as in zebrafish LRRK2 loss-of-function-WD40, another PD model in which a sig-
nificant rescue of motor impairment after L-Dopa treatment was obtained [49] we also tested
L-Dopa at 0.01% (0.5 mM) concentration in the feeding diet of both L-/A+ and L+/A+ mutant
flies. The results presented in Fig 2B show that in Dmmutants the administration of L-Dopa
rescued the impairment of climbing activity only in insects of group I, while worsening the per-
formance in groups II-III.
Fig 2. Effects ofWse on climbing activity. (A-B) Climbing activity of LRRK2 adult males treated withWse 1% as compared with WT and untreated LRRK2
(A) and climbing activity of LRRK2 adult males treated with L-Dopa 0.01% (0.5mM) as compared with WT and untreated LRRK2 (B). Values are
average ± SEM. * indicates p<0.05 at one-way ANOVA followed by LSD post hoc test as compared to WT; ** indicates p<0.05 at one-way ANOVA followed
by LSD post hoc test as compared to LRRK2.
doi:10.1371/journal.pone.0146140.g002
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We also considered the percentages of flies that were able to complete the test and the results
are shown in S1 Fig. In this respect, results confirm the rescue of insects of groups I-II, treated
withWse both as L-/A+ and L+/A+, increase with respect to untreated ones. It is noteworthy
that the percentage of insects of group II that completed the test was 75.2% in WT, 55.6% in
untreated mutants, 80.6% in L-/A+ and 69.5% in L+/A+ Wse-treated mutants. In group III, the
percentage of mutant insects achieving the target was the same no matter the treatment (being
40.9%, 43.4% and 37.9%, respectively) while more than 52% of WT insects accomplished the
task, according to the evaluation criterion (10 sec).
The percentages of flies that were able to complete the test after L-dopa administration are
shown in S1B Fig and demonstrate that the worsening was positively correlated to age and
treatment duration. Thus, the effects ofWse as well as those of L-Dopa administration decrease
with age but that of L-Dopa was drammatic. In fact, group III of L-Dopa-treated flies as L+/A+
the percentage achieving the target was only 15%.
Effects ofWse on the kinetic properties of evoked PSPs recorded from
DLM in LRRK2WD40
In order to detect potential changes in the function of the DLM neuromuscular junction of
LRRK2WD40 flies, from group II, we first evaluated the basal kinetic properties of evoked PSPs
(ePSPs) recorded from the DLM after GFS electrical stimulation. More precisely, we evaluated
the response latency, that is the time between stimulation of the GFS and subsequent muscle
PSP peak, and PSP peak amplitude, that is the maximal muscle depolarization from baseline
value. Fig 3 shows that the basal properties of ePSPs recorded from DLMmuscle of WT ani-
mals results in a latency of 1.84 ± 0.1 ms and in an averaged amplitude of 19 ± 3 mV. Notably,
LRRK2WD40 mutation results in a significant decrease (21%, p< 0.05) of ePSPs latency when
compared to WT animals (Fig 3A and 3B). Such effect was no longer apparent in LRRK2 (L-/
A+) flies that were treated withWse 1%. Surprisingly, latency in LRRK2 treated flies was signifi-
cantly higher with respect to both WT as well as untreated LRRK2 animals. No significant
change was detected in PSP peak amplitude among flies from the different experimental groups
(Fig 3A and 3C).
Effects ofWse on the PSP responses to high frequency stimulation of
GFS of LRRK2WD40
We then tested flies by recording the “frequency of following” which consisted in applying a
train of 10 stimuli at different frequencies (100 or 200 Hz) to GFS. As previously reported [48],
in WT flies, a train of 10 stimulations at 100 Hz induced repetitive responses of DLM with
minimal decrement of PSP amplitude as compared to the first PSP (Fig 4A and 4B). The
response to 100 Hz stimulation in LRRK2WD40 was not different from that observed in WT
(Fig 4A and 4B). In contrast, the response to 100 Hz inWse-treated LRRK2WD40 (L-/A+) flies
revealed a significant decrement of PSP amplitude when compared to the first PSP (Fig 4A and
4B). At the higher frequency of electrical stimulation, the DLM responses of WT started to
decrease in amplitude after the 2nd PSP with 200 Hz stimulations (Fig 4A and 4C). The same
protocol of recording at 200 Hz performed in untreated LRRK2WD40 flies showed that DLM
responded to each of the 10 stimulations whose amplitude of PSPs was only slightly diminished
(Fig 4A and 4C). In treated LRRK2WD40 (L-/A+) insects stimulations at 200 Hz elicited DLM
PSPs which, similarly to WT flies, had amplitudes that decreased with respect to the first PSP.
Two-ways ANOVA revealed a significant effect of the untreated-LRRK2WD40 group compared
to WT when responding to the 200-Hz stimulation (P<0.05)
Drug Effects ofWithania somnifera in a LRRK2 Drosophila Model
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Effects ofWse on the subcellular morphology of LRRK2WD40
Fig 5 shows representative transmission electron microscopy images of thoracic ganglia and
antennal lobes (ALs) of untreated Dm LRRK2 mutants (A) and of 1% and 10%Wse-treated, as
L-/A+ (B and C) and as L+/A+ (D-F), insects. In mitochondria of the thoracic ganglia of LRRK2
mutants, we observed regions with several damaged, swollen, and with clearly fragmented cris-
tae, that we failed to find in the corresponding regions after treatment with 1%Wse (in Fig 5
compare A with B and C). However, after treatment with 10%Wse L+/A+, we observed, in the
Fig 3. Effect of LRRK2 genemutation and treatment withWse 1% (L-/A+) on PSP latency and amplitude recorded fromDrosophila DLM. (A)
Representative traces obtained from three different flies in which PSP latency is calculated as the time (ms) from stimulus application to the peak of PSP
(black arrows). (B, C) Bar graphs represent the mean ± SEM of PSP latency (ms) and amplitude (mV) recorded from flies of the indicated experimental
groups. *indicates p< 0.05 compared to WT, **indicate p<0.05 compared to treated LRRK2; one-way ANOVA, followed by Bonferroni post-hoc test.
doi:10.1371/journal.pone.0146140.g003
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Fig 4. Effect of LRRK2 genemutation and treatment withWse on the “frequency of following” recorded inDrosophilaDLM. (A) Representative
traces obtained from three different flies in which PSPs were evoked in response to 10 stimulations at 100 (top) or 200 Hz (bottom). (B,C) Scatter plot graphs
showing the changes in PSP amplitude following stimulation at 100 (B) or 200 Hz (C). All values are expressed as the mean ± SEM of the % relative to the
amplitude of the first PSP. *indicates p< 0.05 compared to WT andWse-untreated LRRK2 (B) and compared to WT andWse-treated LRRK2 (C), two-way
ANOVA.
doi:10.1371/journal.pone.0146140.g004
Drug Effects ofWithania somnifera in a LRRK2 Drosophila Model
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Fig 5. Samples of transmission electron microscopy images of thoracic ganglia and antennal lobes inDrosophila LRRK2mutant (A) and after
treatment with 1% in L-/A+ insects (B, C) and 10% L+/A+ (D-F) extract ofWse. (A) abnormal mitochondria in the thoracic ganglia neuropil of Drosophila
LRRK2. (B, C) conventional mitochondria in thoracic ganglia of Drosophila LRRK2 after treatment with 1%Wse L-/A+imaged at low (B) and higher
magnification (C). (D, E) abnormal mitochondria in Drosophila LRRK2 thoracic ganglia cell bodies after treatment with 10%WseL+/A+. Note the irregular
electron-dense substance clearly recognizable inside the mitochondria. (F and Inset) numerous endosomes are present inside the antennal lobes neurites of
Drosophila LRRK2 after treatment with 10%Wse. Scale bars are 0.5 μm except in B that is 2.5 μm.
doi:10.1371/journal.pone.0146140.g005
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corresponding regions of the thoracic ganglia, numerous altered mitochondria with a granular,
irregularly shaped electron-dense material in their matrix (Fig 5D and 5E). Moreover after the
same treatment we observed, in Drosophila LRRK2WD40ALs numerous late endosomes/ phago-
somes vacuoles inside presynaptic terminals and dendrites (Fig 5F).
Discussion and Conclusions
One of the aims of the present study was to validate the use of LRRK2WD40 as a model of PD.
In this respect, these mutant flies show reduced lifespan, and motor impairments (face validity)
and mitochondrial dysfunctions (construct validity) that characterize Parkinsonism. Further-
more, this study was aimed at evaluating the action of the standardized extract of the roots of
Withania somnifera (Wse) and its possible neuroprotective effects on the Parkinson’s genetic
model of Drosophila melanogaster LRRK2WD40. Although almost all of the mutations in
LRRK2 have a number of related features, these mutants object of the present study lack, in
particular, the WD40 domain responsible for coding a protein chaperone known to be involved
in a number of cellular functions such as cytoskeletal, neurotransmitter vesicular pathway and
lyso-endosomal activities [25] The results presented here show that the addition of 1%Wse to
standard diet of only LRRK2WD40 adults (L-/A+), but not of L+/A+, significantly a) increases
their lifespan compared to untreated controls and b) improves their locomotor abilities and c)
affects evoked electrophysiological parameters. Furthermore, in thoracic ganglia, under elec-
tron microscopy observation, we found thatWse administration dramatically rescued the
mutation-related loss of mitochondrial structural integrity. Interestingly,Wse chronic adminis-
tration to flies as L+/A+, no matter the concentration, induces a worsening of symptoms associ-
ated with parkinsonism and a further decrease of lifespan as compared to WT controls as well
as to untreated LRRK2WD40 (Fig 1B)
The flight muscle degeneration accompanied by defects in motor activity [50–52] detected
in our study is probably related to dysfunction of dopaminergic neurons. Accordingly, in a zeb-
rafish model LRRK2 loss-of-function in the WD40 domain, it was previously reported a rescue
of motor impairment following L-Dopa administration in the early larval stage from days post
fecundation (DPF) 5 to 6 [49]. Notably, although this and our model of LRRK2 loss-of-function
differ in a number of factors such as animal species, life period and duration of L-Dopa admin-
istration, the present results also demonstrate an improvement of motor deficit (climbing activ-
ity) in the mutants of the group I treated as L-/A+. However, extension of the treatment to flies
of group II and III did not rescue the mutation-dependent impairment but elicited a worsening
in both L-/A+ and L+/A+ treated flies (Fig 2B).
The observed rescue of impaired motor ability byWse administration to LRRK2WD40 Dm
while confirming the condition of mutation-dependent impaired motility, as shown in tests of
climbing (Fig 2), also supports the suggestion thatWse’s effects might be attributable to
increased neurotransmission [53][54]that would result in a better locomotion. Electrophysio-
logical data showed that mutation of the LRRK2 gene was associated with a significant decrease
in PSP latency when compared to WT animals, an effect that was no longer apparent in
LRRK2 (L-/A+) flies that were treated withWse 1%. However, no significant change of PSP
peak amplitude was detected among flies from the different experimental groups suggesting
that in LRRK2WD40 mutants there is a higher probability of (but not necessarily an optimally
coordinated) muscle contraction compared with WT without changes in muscle contraction
per se. Surprisingly,Wse treatment was able to revert the effect of mutation making the
response latencies recorded in LRRK2 (L-/A+) treated flies much higher as compared with both
untreated LRRK2 and WT flies. The decrease in PSP latency together with the decreased
responsiveness to high frequency stimulation observed in untreated-LRRK2WD40 flies appears
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to well correlate with the motility impairment observed in these flies. As for the possible mech-
anism, Augustin and colleagues [48] reported that recording the “frequency of following”, a
GFS train stimulation at 200 Hz induced in WT a significant decrement of PSP amplitude rela-
tive to the first PSP because the intermediary synapses do not have sufficient time to recover
between stimuli. Conversely, a stimulation train at 200 Hz performed in untreated LRRK2WD40
flies showed that, relative to the first PSP, the amplitude of PSPs was only slightly diminished,
starting from the second response, and treatment with 1%Wsemade the responses similar to
those observed in WT. Thus, the effect ofWse on the functional changes associated with the
mutation clearly discloses a beneficial aspect of this treatment. At this time, we cannot explain
in deep details the abnormal effect ofWse treatment in LRRK2 flies (i.e. increased PSP latency
and exacerbated effect on 100 Hz response vs WT), and this might at least in part be justified
recalling the complexity of the projection pathway from the brain to the thoracic ganglion,
where axons form electrical synapses with interneurons and the latter form chemical synapses
on each motor neuron innervating the DLMs [55][56]. However, mutation of LRRK2WD40
may be correlated with a significant impairment in neurotransmitter release from presynaptic
terminals [25][57].
The impaired motility shown by the LRRK2 mutants is paralleled by the presence of scat-
tered abnormal mitochondria in their thoracic ganglia, an observation corroborated by other
studies that suggest the involvement of LRRK2WD40 in mitochondrial homeostasis, responsible
of mitochondrial degradation[58][59]. Intriguingly, the conventional mitochondrial morphol-
ogy of LRRK2WD40 flies observed after treatment with 1%Withania extract, and paralleled by
an improvement in their motor capacity, suggests thatWsemay also act suppressing mito-
chondrial dysfunction, as has been recently demonstrated for a green tea-derived catechin, epi-
gallocatechin gallate (EGCG) [59] and as well as already demonstrated in the case of the
mutant PINK1B9 treated with the standardized seeds extract of another plant,Mucuna pruriens
[33].
In conclusion, based on our results we can infer that the LRRK2 loss-of-function in the
WD40 domain is a plausible model that recapitulates some of the essential features of Parkin-
sonism and that the extract ofWs can be usefully employed to counteract some deficits associ-
ated with this condition. However, as demonstrated by Poddighe et al., [33] afterMucuna
pruriens administration to Dm PINK1B9 mutant model of PD, the use of a whole herbal extract
requires careful assessment. In fact, the effects ofWse on LRRK2WD40 might also be related to
age (group I vs III), length of exposure (L-/A+ vs L+/A+) andWse (0.1% vs 1% vs 10%) concen-
trations as suggested by the observation of its effects on climbing (Fig 2A and 2C) as well as on
life duration (Fig 1C and 1D). Indeed, the negative effect of 10%Wse both onWT (Fig 1B) and
on the loss-of-function LRRK2WD40mutant indicates that one or more components of the
extract, when administered chronically and at a concentration higher than optimal, may have
toxic effects. This conclusion is supported by the observation that chronic administration of
Wse to flies as L+/A+, no matter the concentration, and also at 10% to L-/A+, induces a worsen-
ing of symptoms associated with parkinsonism and a further reduction of lifespan as compared
to WT controls and untreated LRRK2WD40. This observation also indicates thatWse shows a
concentration threshold, below which it does not work; b) has an optimal value for its effects;
but c) whose effects at higher concentrations and/or after longer exposures became toxic. As
discussed above, this suggests thatWse exerts its effects -as a drug- following a hormesis-like
dose-response curve [60] and further highlights the need to assess the proper concentration of
Wse. In this regard, the presence of numerous large sized lysosomes observed exclusively in the
ALs of Drosophila LRRK2WD40 treated with 10%Wse, corroborates its toxic effect, since lyso-
somes increases in number and size are one of the more common cause of degenerative brain
disorders [61].
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Supporting Information
S1 Fig. Percentages of insects able to achieve the test. (A-B) Percentages of adult males WT,
LRRK2,Wse 1% treated LRRK2 (A) and L-Dopa 0.01% (0.5mM) treated LRRK2 (B), that
could climb unto, or above, the line drawn at 6 cm from the bottom of the tube within 10 sec-
onds.Treatments were administered to flies both only when adults (L−/A+) and from their lar-
val stage to the end of their life-cycle (L+/A+), and their effects were assayed at three different
age steps (I: 3–6; II: 10–15; III: 20–25 days) of flies’ life-span. Values are average ± SEM.  indi-
cates p<0.05 at one-way ANOVA followed by LSD post hoc test as compared to WT;  indi-
cates p<0.05 at one-way ANOVA followed by LSD post hoc test as compared to LRRK2.
(TIF)
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